



J. B. Chemicals & Pharmaceuticals Limited

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/06/2013

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended
		30/06/2013	31/03/2013	30/06/2012	31/03/2013
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations				
	a. Net sales (Net of excise duty)	22,916.67	19,772.75	18,484.71	79,446.05
	b. Other Operating Income	606.13	741.59	489.79	2,196.20
	Total Income from Operations (Net) (a+b)	23,522.80	20,514.34	18,974.50	81,642.25
2	Expenses				
	a. Cost of materials consumed	7,825.35	6,210.78	6,132.79	26,190.38
	b. Purchases of stock-in-trade	2,239.14	2,099.38	1,396.77	7,155.17
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(207.48)	(101.12)	354.55	480.97
	d. Employees benefits expense	3,390.01	3,134.89	3,079.53	12,012.87
	e. Depreciation and amortization expense	750.00	600.58	601.35	2,439.58
	f. Exchange Fluctuation Transactional (Gain)/Loss	3.58	(88.82)	895.92	1,582.58
	g. Other Expenses	6,233.38	6,528.47	5,116.76	23,746.56
	Total Expenses	20,233.98	18,384.16	17,577.67	73,608.11
3	Profit/(Loss) from Operations before Other Income and Finance Cost (1-2)	3,288.82	2,130.18	1,396.83	8,034.14
4	Other Income	151.52	256.77	270.01	2,596.07
5	Profit/(Loss) from Ordinary Activities before Finance Cost (3+4)	3,440.34	2,386.95	1,666.84	10,630.21
6	Finance Cost	146.88	116.42	124.13	524.18
7	Profit/(Loss) from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	3,293.46	2,270.53	1,542.71	10,106.03
8	Exchange Fluctuation Translation Gain / (Loss)	(544.16)	12.80	(961.77)	668.44
9	Profit from Ordinary Activities before Tax (7+-8)	2,749.30	2,283.33	580.94	10,774.47
10	Tax expenses	716.76	308.10	150.09	2,280.62
11	Net Profit for the period from Ordinary Activities after Tax (9-10)	2,032.54	1,975.23	430.85	8,493.85
12	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,694.24	1,694.15	1,694.15	1,694.15
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year (see note no. 3)	-	-	-	*99,206.03
14	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	2.40	2.33	0.51	10.03
	(2) Diluted	2.40	2.33	0.51	10.03

Sl. No.	PART II - Particulars	Quarter ended			Year ended
		30/06/2013	31/03/2013	30/06/2012	31/03/2013
		Unaudited	Audited	Unaudited	Audited
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of Shares	37,385,603	37,381,103	37,380,603	37,381,103
	- Percentage of shareholding	44.13	44.13	44.13	44.13
2	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered	-	-	-	-
	- Number of Shares	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	47,326,197	47,326,197	47,326,697	47,326,197
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.87	55.87	55.87	55.87

B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/06/2013
Pending at the beginning of the quarter	Nil
Received during the quarter	2
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	Nil

NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on July 26, 2013.
- The statutory auditors have carried out limited review of the above financial results for the quarter ended on June 30, 2013.
- *Included in the figure of accumulated reserves as of March 31, 2013 is net profit after tax on sale of the company's Russia-CIS OTC business undertaking (accounted vide financial statements for the financial year ended on March 31, 2012). In relation to the said sale, a part of the proceeds was kept in an Escrow Account with a bank in India. The Purchaser raised claims in relation to the transaction of the said sale and consequently the amount in such Escrow Account was not released, following which there was a series of meetings, correspondences, etc. However, by a mutual decision reached on July 16, 2013, the Parties have agreed that the consideration paid for the sale of the said business be revised downward by Rs. 64.50 crores. Thus, out of the balance in the said Escrow Account, a sum of Rs. 64.50 crores has been released to the Purchaser, while the balance amount being Rs. 73.07 crores has been released to the company. Accordingly, the said figure of reserves is subject to a reduction of Rs. 64.50 crores as aforesaid, which will be appropriately reflected in the results for the quarter ending on September 30, 2013.
- The figures in respect of the results for preceding quarter ended on March 31, 2013 are balancing figures between the audited financial results in respect of the full financial year ended on March 31, 2013 and the published year to date figures up to the third quarter ended on December 31, 2012.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.

For J.B. Chemicals & Pharmaceuticals Ltd.

Sd/-

Place : Mumbai
Date : July 26, 2013

J.B.Mody
Chairman & Managing Director

